Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
M&A / Property

Aequus Announces Completion of Previously Announced Sale of ZIMED(R) PF

Aequus Offloads Final Asset for Half-Million as NEX Transfer Signals Corporate Wind-Down

By The Northwire Desk — AI Analysis Mar 31, 2026 · 12:40 AQS · 0.005 Aequus Pharmaceuticals Inc.
Executive Summary
  • The March 31, 2026 release confirms the completion of the previously announced sale of the ZIMED PF product to Luvo Medical Technologies Ltd. for approximately $531,693.
  • The original purchase agreement was amended to replace a 6% ongoing royalty with a one-time lump-sum royalty payment of $131,693, increasing total proceeds from the initially anticipated ~$400,000.
  • The company's TSX Venture Exchange listing will be transferred to the NEX board effective around April 3, 2026.
  • Historical context from the November 12, 2025 disclosure reveals ongoing corporate governance and regulatory friction, including a cease-trade order against director nominee Marc Lustig and conditional language surrounding a proposed share consolidation.
  • The progression from regulatory scrutiny and conditional restructuring to asset divestiture and exchange demotion indicates a clear corporate wind-down trajectory.
Material Impact
  • The transaction is a completion of a previously announced deal, making it expected rather than novel. The shift from a 6% ongoing royalty to a lump sum eliminates future recurring revenue in exchange for immediate, albeit immaterial, cash.
  • The NEX board transfer is a definitive negative catalyst. It signals that the company no longer meets active trading or operational requirements, severely restricts liquidity, and typically precedes voluntary delisting, bankruptcy, or complete liquidation.
  • The ~$531,000 proceeds are negligible for a pharmaceutical entity and will likely be consumed by administrative overhead, regulatory compliance, and potential undisclosed liabilities.
  • Overall impact is negative but fully aligned with the company's deteriorating operational and regulatory status.
AQS · Price
Company Overview
  • Aequus Pharmaceuticals operated in the specialty pharmaceutical sector, focusing on commercializing niche therapeutic products.
  • The flagship project, ZIMED PF, has been fully divested. The company no longer holds commercial assets or an active development pipeline.
  • Management appears to be executing a controlled wind-down rather than pursuing growth or new product development.
Read the original news release →